{"filing":{"accession_number":"0001171843-26-005686","cik":"0001540159","ticker":"EDSA","company_name":"Edesa Biotech, Inc.","form":"8-K","filing_date":"2026-08-20","report_date":"2026-08-19","primary_document":"f8k_081726.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1540159/000117184326005686/f8k_081726.htm"},"events":[{"id":28867,"run_id":26420,"accession_number":"0001171843-26-005686","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"Edesa Biotech entered into an underwriting agreement on August 19, 2026 for a registered public offering of 3,870,500 common shares with warrants and 675,000 pre-funded warrants, raising approximately $25 million in gross proceeds ($23.1 million net). The offering includes an underwriter option for an additional 681,825 shares and represents a material dilutive equity issuance typical of clinical-stage biotech capital raises.","company_name":"Edesa Biotech, Inc.","ticker":"EDSA","filing_date":"2026-08-20","form":"8-K","submitted_at":null,"items":[{"id":30938,"accession_number":"0001171843-26-005686","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Edesa Biotech entered into an underwriting agreement on August 19, 2026 for a registered public offering of 3,870,500 common shares with warrants and 675,000 pre-funded warrants, raising approximately $25 million in gross proceeds ($23.1 million net). The offering includes dilutive equity issuance and warrant exercises that will substantially increase share count. This is a material capital-raising event typical of clinical-stage biotech companies and would significantly affect investor assessment of ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:17:49.821169+00:00","company_name":"","ticker":null,"filing_date":""},{"id":30939,"accession_number":"0001171843-26-005686","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a registered public offering of common shares and pre-funded warrants with accompanying common share warrants, priced at $5.50 per unit with gross proceeds of approximately $25.0 million. This is a material equity issuance by a clinical-stage biopharmaceutical company that will dilute existing shareholders. The offering includes 3,870,500 common shares plus up to 675,000 pre-funded warrants, plus an underwriter option for an additional 681,825 shares—all registered under an effective Form S-3 shelf registration statement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:17:49.821169+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30938,"accession_number":"0001171843-26-005686","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Edesa Biotech entered into an underwriting agreement on August 19, 2026 for a registered public offering of 3,870,500 common shares with warrants and 675,000 pre-funded warrants, raising approximately $25 million in gross proceeds ($23.1 million net). The offering includes dilutive equity issuance and warrant exercises that will substantially increase share count. This is a material capital-raising event typical of clinical-stage biotech companies and would significantly affect investor assessment of ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:17:49.821169+00:00","company_name":"Edesa Biotech, Inc.","ticker":"EDSA","filing_date":"2026-08-20"},{"id":30939,"accession_number":"0001171843-26-005686","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a registered public offering of common shares and pre-funded warrants with accompanying common share warrants, priced at $5.50 per unit with gross proceeds of approximately $25.0 million. This is a material equity issuance by a clinical-stage biopharmaceutical company that will dilute existing shareholders. The offering includes 3,870,500 common shares plus up to 675,000 pre-funded warrants, plus an underwriter option for an additional 681,825 shares—all registered under an effective Form S-3 shelf registration statement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:17:49.821169+00:00","company_name":"Edesa Biotech, Inc.","ticker":"EDSA","filing_date":"2026-08-20"}]}